|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0110 AUD | 0.00% |
|
-8.33% | -26.67% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.3M 3.77M 3.51M 3.23M 6.06M 411M 41.67M 16.31M 204M 16.13M 15.79M 703M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.23M 5.47M 5.09M 4.68M 8.78M 595M 60.42M 23.65M 295M 23.39M 22.89M 1.02B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 week | -8.33% | ||
| Current month | -8.33% | ||
| 1 month | -15.38% | ||
| 6 months | -26.67% | ||
| Current year | -26.67% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.01 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.78 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | -8.33% | -38.89% | -78.43% | 3.95M | ||
| +0.42% | +2.21% | +16.10% | +73.68% | 49.38B | ||
| +1.45% | +5.24% | +59.84% | +120.96% | 36.35B | ||
| +1.02% | +3.23% | -7.19% | +24.32% | 11.87B | ||
| +0.76% | -1.40% | +11.62% | +75.64% | 11.53B | ||
| +0.38% | +1.16% | +31.33% | +131.86% | 8.99B | ||
| +3.41% | +3.89% | +50.47% | -3.96% | 7B | ||
| -0.51% | -0.85% | +11.77% | +33.26% | 6.76B | ||
| +1.62% | +1.00% | +2.97% | +182.03% | 6.46B | ||
| -1.32% | -6.80% | -33.10% | -2.26% | 5.49B | ||
| Average | +0.77% | -1.69% | +10.49% | +55.71% | 14.38B | |
| Weighted average by Cap. | +0.88% | +0.32% | +24.83% | +81.63% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.55M 3.12M 2.9M 2.67M 5.01M 339M 34.44M 13.48M 168M 13.34M 13.05M 581M | 1.19M 830K 729K 679K 624K 1.17M 79.32M 8.05M 3.15M 39.34M 3.12M 3.05M 136M |
| Net income | -5.8M -4.05M -3.55M -3.31M -3.04M -5.7M -387M -39.24M -15.36M -192M -15.19M -14.86M -662M | -5.94M -4.15M -3.64M -3.39M -3.12M -5.84M -396M -40.22M -15.74M -197M -15.57M -15.24M -679M |
| Net Debt | 759K 530K 465K 433K 398K 746K 50.59M 5.13M 2.01M 25.09M 1.99M 1.95M 86.69M | 2.77M 1.93M 1.7M 1.58M 1.45M 2.73M 185M 18.75M 7.34M 91.64M 7.26M 7.1M 317M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/07/26 | A$0.0110 | 0.00% | 1,429,995 |
| 28/07/26 | A$0.0110 | 0.00% | 2,638,948 |
| 27/07/26 | A$0.0110 | -8.33% | 169,956 |
| 24/07/26 | A$0.0120 | 0.00% | 30,408 |
| 23/07/26 | A$0.0120 | 0.00% | 111,592 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















